Recent advances in engineered nanozymes for precision lung cancer therapy
Fushuang Zheng, Hongyan Zhang, Feng Guo, Xiajie Wu, Kuanbing Chen, Nana Li, Hengyi Yan · 2026
Read Recent advances in engineered nanozymes for precision lung cancer therapy by Fushuang Zheng, Hongyan Zhang, Feng Guo, Xiajie Wu, Kuanbing Chen, Nana Li, Hengyi Yan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13312534.txt.
Description
Fushuang Zheng and colleagues review, in a 2026 article, new work on engineered nanozymes for lung cancer therapy. Lung tumors resist treatment by adapting, and standard care struggles to reshape the tumor microenvironment, the neighborhood that shields cancer from drugs and immunity alike.
The authors frame nanozymes, catalytic nanomaterials that mimic enzymes, as active agents rather than passive carriers. By generating reactive species, adjusting oxygen, and running cascade reactions, these particles disturb the tumor's redox balance and metabolic dependencies. They sensitize it to chemotherapy, radiation, and light-based treatments, and provoke immunogenic cell death that recruits the immune system. The review lays out design logic around setting when and where the catalysts switch on, then maps the barriers still blocking use in patients and a route toward next-generation enzyme-like medicine.
Catalog record
| CREATOR | Fushuang Zheng, Hongyan Zhang, Feng Guo, Xiajie Wu, Kuanbing Chen, Nana Li, Hengyi Yan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 100846 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |